Product Description
LY2300559 is a dual metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator and cysteinyl leukotriene receptor 1 (CysLTR1) antagonist. Eli Lilly was developing LY2300559 for the prevention of migraine (Sourced from: https://drugs.ncats.io/drug/Z572ZBT8XL)
Mechanisms of Action: GRM2 Modulator, CysLT Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Eli Lilly
Company Location: Eastern America
Company Founding Year: 1876
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Migraine Disorders|Headache Disorders
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01184508 |
I1N-MC-CDBE | P2 |
Terminated |
Headache Disorders|Migraine Disorders |
2012-04-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|